6.9101
Schlusskurs vom Vortag:
$7.70
Offen:
$7.6
24-Stunden-Volumen:
156.90K
Relative Volume:
1.37
Marktkapitalisierung:
$861.22M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-4.6067
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
-22.74%
1M Leistung:
-4.60%
6M Leistung:
-57.13%
1J Leistung:
-86.78%
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MRSN
Mersana Therapeutics Inc
|
6.9101 | 38.39M | 36.86M | -171.67M | -171.05M | -1.50 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.15 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
567.30 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.78 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.97 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
297.91 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-06 | Eingeleitet | William Blair | Outperform |
2024-11-15 | Fortgesetzt | Citigroup | Buy |
2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
2023-07-27 | Herabstufung | Truist | Buy → Hold |
2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-06-15 | Eingeleitet | Guggenheim | Buy |
2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-01-20 | Eingeleitet | Citigroup | Buy |
2022-11-21 | Eingeleitet | Truist | Buy |
2021-10-15 | Fortgesetzt | BTIG Research | Buy |
2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
2020-12-03 | Eingeleitet | Stifel | Buy |
2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
2020-04-29 | Eingeleitet | BTIG Research | Buy |
2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
What is Mersana Therapeutics Inc. company’s growth strategyRapid profit acceleration - jammulinksnews.com
Should I hold or sell Mersana Therapeutics Inc. stock in 2025Exceptional stock performance - jammulinksnews.com
What are the latest earnings results for Mersana Therapeutics Inc.Maximize returns with disciplined trading approaches - jammulinksnews.com
Does Mersana Therapeutics Inc. stock perform well during market downturnsBreakthrough capital growth - jammulinksnews.com
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Metal.it
How Mersana Therapeutics Inc. stock performs during market volatilityTop Growth Low Risk Stocks - metal.it
MRSN Trading Halted Due to Pending News - GuruFocus
What analysts say about Mersana Therapeutics Inc. stockSuperior stock selection - PrintWeekIndia
Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025 - Insider Monkey
What drives Mersana Therapeutics Inc. stock priceRapid wealth accumulation - PrintWeekIndia
Will Mersana Therapeutics Inc. stock split in the near futureFree Investment Case Studies - jammulinksnews.com
Mersana Therapeutics to execute 1-for-25 reverse stock split - MSN
Mersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq
Mersana Therapeutics Implements Reverse Stock Split to Meet Nasdaq Listing Requirements - AInvest
Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan - Investing.com Australia
Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan By Investing.com - Investing.com South Africa
Mersana Therapeutics to implement 1-for-25 reverse stock split Friday - Investing.com Australia
Mersana Therapeutics to implement 1-for-25 reverse stock split Friday By Investing.com - Investing.com South Africa
Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Sp - GuruFocus
Mersana Therapeutics Announces Reverse Stock Split - TipRanks
Mersana Therapeutics to implement 1-for-25 reverse stock split - Investing.com India
Mersana Therapeutics to implement 1-for-25 reverse stock split By Investing.com - Investing.com Nigeria
Mersana (MRSN) Announces 1-for-25 Reverse Split to Retain Nasdaq Listing - Stock Titan
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewswire
Mersana's 1:25 Reverse Split Aims to Save Nasdaq Listing: Key Details for Investors - Stock Titan
Mersana Therapeutics Inc. Stock Analysis and ForecastSuperior stock growth - Autocar Professional
MRSN: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
Is Mersana Therapeutics Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mersana Therapeutics Inc-Aktie (MRSN) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
DeSchuytner Brian | SVP, COO & CFO |
Jan 16 '25 |
Sale |
0.58 |
8,470 |
4,913 |
121,393 |
Carvajal Alejandra | SVP, Chief Legal Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
83,392 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):